CANBridge Life Sciences
Suite 303A, Building E, Wangjing Pioneer Park, No.
Chaoyang District
Beijing
100102
China
Tel: 86-10-84148018
Fax: 86-10-84148017
Website: http://www.canbridgepharma.com/
Email: info@canbridgepharma.com
43 articles about CANBridge Life Sciences
-
CANbridge and UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy (CAN203) Improves Lifespan and Motor Function in Mice When Administered via Intracerebroventricular Injection
5/18/2023
CANbridge Pharmaceuticals Inc. announced that data on a novel second-generation spinal muscular atrophy gene therapy, developed under the CANbridge and UMass Chan Medical School research agreement, was presented as a poster at the American Society of Gene and Cell Therapy 26th Annual Meeting, in Los Angeles.
-
CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research
5/5/2023
CANbridge Pharmaceuticals, Inc., a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced that it has appointed Jason West, Ph.D., to the position of Vice President, Head of Gene Therapy Research, effective immediately.
-
CANbridge-UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy Animal Data to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
5/3/2023
CANbridge Pharmaceuticals Inc. announced that data on the novel second-generation gene therapy, developed under the CANbridge and UMass Chan Medical School research agreement, will be presented at the American Society of Gene and Cell Therapy 26th Annual Meeting, May 16-20, Los Angeles, CA.
-
CANbridge Pharmaceuticals Spinal Muscular Atrophy Gene Therapy Abstract Accepted for Presentation at the American Society for Gene and Cell Therapy annual Meeting
4/12/2023
CANbridge Pharmaceuticals, Inc. announced that the American Society for Gene and Cell Therapy has accepted the following abstract for presentation at the ASCGT Annual Meeting, May 16-20, in Los Angeles, CA.
-
CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2022
3/31/2023
CANbridge Pharmaceuticals, Inc., a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced financial results for the twelve months ended 2022 and corporate update.
-
Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database
3/17/2023
CANbridge Pharmaceuticals, Inc. announced that long-term follow up data from the Phase 1/2 study of CAN008 plus temozolomide/radiotherapy in newly diagnosed glioblastoma multiforme showed a long-term survival rate of 67% at five years, three years after the trial ended.
-
CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver Disease
10/27/2022
CANbridge Pharmaceuticals Inc. announced that the company’s partner Mirum Pharmaceuticals, Inc. reported positive topline data from its Phase 3 MARCH study evaluating the safety and efficacy of LIVMARLI® oral solution in patients with progressive familial intrahepatic cholestasis.
-
CANbridge Pharmaceuticals to Participate in Upcoming Investor Conferences - October 13, 2022
10/13/2022
CANbridge Pharmaceuticals, Inc., a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced that it will take part in two upcoming investor conferences.
-
CANbridge Pharmaceuticals to Participate in Two Investor Conferences in September 2022
9/13/2022
CANbridge Pharmaceuticals, Inc. announced that it will be participating in two upcoming investor conferences.
-
MacroGenics' Phase II trial shuts down after a patient death believed to be related to enoblituzumab combo, while Exelixis' Cabometyx combo improves PFS in renal cell carcinoma.
-
The ASGCT's 25th Annual Meeting features the latest scientific research in genetics and cellular therapies. Read on for highlights from the meeting.
-
CANbridge-UMass Chan Medical School Gene Therapy Research to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
5/4/2022
CANbridge Pharmaceuticals Inc. announced that data from its gene therapy research agreement with the Horae Gene Therapy Center, at the UMass Chan Medical School, will be presented at the ASGCT 25th Annual Meeting, being held in Washington D.C.
-
First Patient Dosed in CAN106 Phase 1b/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
3/28/2022
The multi-center, open-label, Phase 1b/2 study to evaluate the tolerability, efficacy, safety and PK/PD of CAN106 administered intravenously to complement inhibitor treatment-naïve PNH patients, is under the direction of principal investigator, Dr. Bing Han, Director of Hematology, at the Peking Union Medical College Hospital.
-
CORRECTING and REPLACING CANbridge Announces Approval of CAN108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone
2/25/2022
CANbridge Pharmaceuticals, Inc. announced that CAN108, a treatment for Alagille syndrome, has been approved under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone in China, which will allow it to be imported and used as an urgently needed drug in the zone.
-
CANbridge Pharmaceuticals Appoints Dr. Lan Hu as New Independent Director
2/17/2022
CANbridge Pharmaceuticals, Inc. announced that it has appointed Lan Hu, Ph.D. as the independent, nonexecutive Director of the Board of Directors and member of the remuneration committee, effective as of February 16, 2022.
-
CANbridge Reports Positive Top-Line CAN106 Phase 1 Data
2/7/2022
CANbridge Pharmaceuticals, Inc. announced top-line results from a Phase 1 single ascending dose study of CAN106, a novel, long-acting, anti-C5 complement recombinant human monoclonal antibody that is under development for the treatment of complement-mediated diseases, in 31 healthy volunteers in Singapore.
-
CANbridge Pharmaceuticals CAN108 New Drug Application (NDA) for Alagille Syndrome Accepted by China’s National Medical Products Administration
1/18/2022
CANbridge Pharmaceuticals Inc. announced that the Chinese National Medical Products Administration has accepted the New Drug Application for CAN108 ) for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.
-
Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.
-
Shanghai Foundation for Rare Disease Appoints CANbridge CEO, James Xue, Deputy Director General
1/6/2020
CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that James Xue, PhD, CANbridge Founder, Chairman and CEO, was named one of six Deputy Director Generals at the Second General Election Meeting of the Shanghai Foundation for Rare Disease, in Shanghai, China on December 21st.
-
CANbridge Receives Hong Kong Department of Health Market Approval for NERLYNX®
11/5/2019
First CANbridge Oncology Targeted Therapy to be Approved